EE05270B1 - Mittekristallilise kaltsiumatorvastatiini valmistamismeetod - Google Patents

Mittekristallilise kaltsiumatorvastatiini valmistamismeetod

Info

Publication number: EE05270B1
Authority: EE; Estonia
Prior art keywords: atorvastatin; crystalline; calcium; oratorvastatin; preparation
Prior art date: 2001-01-23

Application number

EEP200300333A

Other languages

English (en)

Estonian (et)

Inventor

Sorsak Gorazd

Original Assignee

Lek Pharmaceutical And Chemical Company D.D.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-01-23

Filing date

2002-01-22

Publication date

2010-02-15

2002-01-22 Application filed by Lek Pharmaceutical And Chemical Company D.D. filed Critical Lek Pharmaceutical And Chemical Company D.D.

2003-10-15 Publication of EE200300333A publication Critical patent/EE200300333A/xx

2010-02-15 Publication of EE05270B1 publication Critical patent/EE05270B1/xx

Links

OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title 1
229910052791 calcium Inorganic materials 0.000 title 1
239000011575 calcium Substances 0.000 title 1
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical class C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 abstract 3
OUCSEDFVYPBLLF-KAYWLYCHSA-N 5-(4-fluorophenyl)-1-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-n,4-diphenyl-2-propan-2-ylpyrrole-3-carboxamide Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@H]2OC(=O)C[C@H](O)C2)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 OUCSEDFVYPBLLF-KAYWLYCHSA-N 0.000 abstract 2
125000006239 protecting group Chemical group 0.000 abstract 2
230000015572 biosynthetic process Effects 0.000 abstract 1
159000000007 calcium salts Chemical class 0.000 abstract 1
125000006244 carboxylic acid protecting group Chemical group 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Obesity (AREA)
Pyrrole Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

EEP200300333A 2001-01-23 2002-01-22 Mittekristallilise kaltsiumatorvastatiini valmistamismeetod EE05270B1 (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SI200100010A SI20814A (sl)	2001-01-23	2001-01-23	Priprava amorfnega atorvastatina
PCT/IB2002/000161 WO2002059087A1 (fr)	2001-01-23	2002-01-22	Preparation de calcium d'atorvastatine non cristallin

Publications (2)

Publication Number	Publication Date
EE200300333A EE200300333A (et)	2003-10-15
EE05270B1 true EE05270B1 (et)	2010-02-15

Family

ID=20432812

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200300333A EE05270B1 (et)	2001-01-23	2002-01-22	Mittekristallilise kaltsiumatorvastatiini valmistamismeetod

Country Status (27)

Country	Link
US (2)	US6750353B2 (fr)
EP (1)	EP1373202B1 (fr)
JP (1)	JP4336106B2 (fr)
KR (1)	KR100882066B1 (fr)
CN (1)	CN1260213C (fr)
AT (1)	ATE294159T1 (fr)
AU (1)	AU2002219455B2 (fr)
BG (1)	BG108017A (fr)
BR (1)	BR0206637A (fr)
CA (1)	CA2435954C (fr)
CZ (1)	CZ20031988A3 (fr)
DE (1)	DE60203894T2 (fr)
DK (1)	DK1373202T3 (fr)
EE (1)	EE05270B1 (fr)
ES (1)	ES2240748T3 (fr)
HR (1)	HRP20030575B1 (fr)
HU (1)	HU227535B1 (fr)
IL (2)	IL157068A0 (fr)
MX (1)	MXPA03006548A (fr)
PL (1)	PL209428B1 (fr)
RS (1)	RS51010B (fr)
RU (1)	RU2324679C2 (fr)
SI (2)	SI20814A (fr)
SK (1)	SK286593B6 (fr)
UA (1)	UA73829C2 (fr)
WO (1)	WO2002059087A1 (fr)
ZA (1)	ZA200305307B (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7411075B1 (en)	2000-11-16	2008-08-12	Teva Pharmaceutical Industries Ltd.	Polymorphic form of atorvastatin calcium
IL156055A0 (en)	2000-11-30	2003-12-23	Teva Pharma	Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en)	2000-11-30	2009-03-10	Teva Pharaceutical Industries Ltd.	Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
CA2622477A1 (fr)	2000-12-27	2002-07-04	Teva Pharmaceutical Industries Ltd.	Formes cristallines d'atorvastatine
WO2002068335A2 (fr) *	2001-02-27	2002-09-06	Council Of Scientific And Industrial Research	Préparation de compositions à base d'huiles essentielles pour la désinfection de liquides potables
BR0210666A (pt)	2001-06-29	2004-10-05	Warner Lambert Co	Formas cristalinas do sal de cálcio do ácido [r-(r,r)]-2-(4-fluorofenil)-beta, delta-dihidróxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)c arbonil]-1h-pirrol-1-heptanóico (2:1) (atorvastatina)
WO2005033078A1 (fr) *	2003-10-07	2005-04-14	Biocon Limited	Procede de production d'atorvastatine calcique
HU227124B1 (en) *	2001-09-14	2010-07-28	Egis Gyogyszergyar Nyilvanosan	Polymorphs of 1-pyrrole derivative, intermediate for the preparation of atorvastatin
HRP20040767A2 (en)	2002-02-19	2004-12-31	Teva Pharma	Desolvating solvates of atorvastatin hemi-calcium
ITMI20020907A1 (it) *	2002-04-29	2003-10-29	Chemi Spa	Processo di preparazione della forma amorfa del sale di calcio della atorvastatina
CA2385529A1 (fr) *	2002-05-21	2003-11-21	Bernard Charles Sherman	Formulations posologiques stables contenant de l'atorvastatin calcium
AU2004228607B2 (en) *	2003-04-11	2011-01-27	Lek Pharmaceuticals D.D.	Process for the preparation of amorphous calcium salt of atorvastatin
US7790197B2 (en)	2003-06-09	2010-09-07	Warner-Lambert Company Llc	Pharmaceutical compositions of atorvastatin
US20050271717A1 (en)	2003-06-12	2005-12-08	Alfred Berchielli	Pharmaceutical compositions of atorvastatin
US7655692B2 (en)	2003-06-12	2010-02-02	Pfizer Inc.	Process for forming amorphous atorvastatin
JP2007516166A (ja)	2003-07-02	2007-06-21	エギシュ　ヂョヂセルヂャール　エルテー	血小板凝集阻害剤の無晶形の製法
AU2003247327A1 (en) *	2003-07-15	2005-01-28	Eos Eczacibasi Ozgun Kimyasal Urunler Sanyi Ve Ticaret A.S.	Process for the preparation of amortphous atorvastatin calcium without interconversion of any crystalline form
EP1711489B1 (fr) *	2003-12-29	2012-12-26	LEK Pharmaceuticals d.d.	Procede pour preparer un compose amorphe d'acide (4r-cis)-6-[2-[3-phenyl-4-(phenylcarbamoyl)-2-(4-fluorophenyl)-5-(1-methyl)-pyrrol-1-yl]-ethyl]-2,2-dimethyl-[1,3]-dioxane-4-yl-acetique
WO2005092852A1 (fr)	2004-03-17	2005-10-06	Ranbaxy Laboratories Limited	Procede de production d'atorvastatine calcique sous forme amorphe
CA2649054A1 (fr)	2004-05-05	2005-11-10	Pfizer Products Inc.	Formes salines d'acide [r-(r, r)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoique
CA2573969C (fr) *	2004-07-16	2014-02-04	Lek Pharmaceuticals D.D.	Produits de degradation oxydante du calcium d'atorvastatine
JP2008506764A (ja)	2004-07-20	2008-03-06	ワーナー−ランバートカンパニーリミテッドライアビリティーカンパニー	［Ｒ−（Ｒ＊，Ｒ＊）］−２−（４−フルオロフェニル）−β、δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−［（フェニルアミノ）カルボニル］−１Ｈ−ピロール−１−ヘプタン酸カルシウム塩（２：１）の新規形態
WO2006011155A1 (fr) *	2004-07-26	2006-02-02	Apollo International Limited	Procede en enceinte unique pour calcium d'atorvastatine amorphe
US7645888B2 (en)	2004-08-27	2010-01-12	Biocon Limited	Process for the production of amorphous atorvastatin calcium
WO2006046109A1 (fr)	2004-10-28	2006-05-04	Warner-Lambert Company Llc	Procede de formation d'atorvastatine amorphe
ES2270722B1 (es) *	2005-09-15	2008-03-01	Ercros Industrial, S.A.	Procedimiento para la obtencion de atorvastatina calcica amorfa.
US20090216029A1 (en) *	2005-09-16	2009-08-27	Yatendra Kumar	Process for the production of atorvastatin calcium in amorphous form
CA2547216A1 (fr) *	2005-09-21	2007-03-21	Renuka D. Reddy	Procede de recuit de l'atorvastatine amorphe
ATE466840T1 (de)	2005-11-21	2010-05-15	Warner Lambert Co	Neue formen von är-(r,r)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-( -methylethyl)-3-phenyl-4- ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure magnesium
EP1810667A1 (fr)	2006-01-20	2007-07-25	KRKA, tovarna zdravil, d.d., Novo mesto	Composition pharmaceutique contenant de l'atorvastatin amorphé
US20090099371A1 (en) *	2006-01-31	2009-04-16	Runjhun Gupta	Process for the preparation of amorphous atorvastatin calcium salt
CN100406438C (zh) *	2006-06-30	2008-07-30	浙江新东港药业股份有限公司	一种无定型阿伐他汀钙的制备方法
WO2008053312A2 (fr) *	2006-11-02	2008-05-08	Cadila Pharmaceuticals Limited	Procédé de préparation d'un sel d'hémicalcium d'atorvastatine amorphe et intermédiaire de ce dernier
KR100833439B1 (ko) *	2007-01-02	2008-05-29	씨제이제일제당 (주)	비결정형 아토르바스타틴 칼슘의 개선된 제조방법
EP2211611B1 (fr) *	2007-10-17	2014-12-10	Todd F. Ovokaitys	Procédé de modification de l'état solide d'un composé et compositions co-amorphes ainsi obtenues
WO2009139730A1 (fr) *	2008-05-13	2009-11-19	Ulkar Kimya San. Ve Tic. A.S.	Fabrication de nouvelles formes non cristallines d'atorvastatine calcique
KR101050722B1 (ko)	2008-12-02	2011-07-21	대웅바이오 주식회사	무정형 아토르바스타틴 칼슘염의 제조방법
US8115015B2 (en) *	2009-01-26	2012-02-14	Cadila Healthcare Limited	Process for the preparation of amorphous atorvastatin calcium
SI2560951T1 (sl) *	2010-04-19	2016-10-28	Dsm Sinochem Pharmaceuticals Netherlands B.V.	Proizvodnja atorvastanina z nizko vsebnostjo etrskih nečistoč
HUP1000299A2 (hu)	2010-06-08	2012-02-28	Nanoform Cardiovascular Therapeutics Ltd	Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
CN102796036B (zh) *	2012-09-12	2014-06-04	江苏阿尔法药业有限公司	一种阿托伐他汀钙的制备方法
US10202598B2 (en)	2014-05-30	2019-02-12	Todd Frank Ovokaitys	Methods and systems for generation, use, and delivery of activated stem cells
US10384985B2 (en)	2014-06-06	2019-08-20	B.K. Consultants, Inc.	Methods and compositions for increasing the yield of, and beneficial chemical composition of, certain plants
WO2015187974A1 (fr)	2014-06-06	2015-12-10	Ovokaitys Todd Frank	Procédés et compositions pour augmenter l'activité biologique de nutriments
CN113321607A (zh) *	2020-02-28	2021-08-31	北京福元医药股份有限公司沧州分公司	一种阿托伐他汀钙中间体的纯化方法
US12246037B2 (en)	2020-12-08	2025-03-11	Todd Frank Ovokaitys	Methods and systems for increased production of stem cells

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4681893A (en)	1986-05-30	1987-07-21	Warner-Lambert Company	Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5216174A (en)	1988-02-22	1993-06-01	Warner-Lambert Co.	Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en)	1989-02-01	1992-03-17	Warner-Lambert Company	Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en)	1988-02-22	1992-06-23	Warner-Lambert Company	Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en)	1988-02-22	1992-09-22	Warner-Lambert Company	Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en)	1988-02-22	1993-09-14	Warner-Lambert Company	Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en)	1988-02-22	1991-03-26	Warner-Lambert Company	Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
FI94339C (fi)	1989-07-21	1995-08-25	Warner Lambert Co	Menetelmä farmaseuttisesti käyttökelpoisen /R-(R,R)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5103024A (en)	1990-10-17	1992-04-07	Warner-Lambert Company	Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en)	1991-10-11	1992-10-13	Warner-Lambert Company	Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5298627A (en)	1993-03-03	1994-03-29	Warner-Lambert Company	Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
IL118778A (en) *	1995-07-03	1999-07-14	Sankyo Co	Pharmaceutical compositions for the treatment of arteriosclerosis and xanthoma containing an hmg-coa reductase inhibitor
GEP20002029B (en)	1995-07-17	2000-04-10	Warner Lambert Company Us	(54) Crystalline [R-(R,R,]–2-(4-Fluorophenyl)-Beta,Delta-Dihydroxy-5-(1-Methyl-Ethyl)-3-Phenyl–4-{Phenylamino) Carbonyl} - 1H - Pyrrole - 1 - Heptanoic Acid Hemi Calcium Salt (Atorvastatin)
HRP960312B1 (en) *	1995-07-17	2001-10-31	Warner Lambert Co	NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R, R)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
HRP960313B1 (en)	1995-07-17	2002-08-31	Warner Lambert Co	Form iii crystalline (r- (r, r)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US6087511A (en)	1996-07-16	2000-07-11	Warner-Lambert Company	Process for the production of amorphous [R-(R,R)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
IN191236B (fr) *	1999-05-25	2003-10-11	Ranbaxy Lab Ltd

2001
- 2001-01-23 SI SI200100010A patent/SI20814A/sl not_active IP Right Cessation
2002
- 2002-01-22 RU RU2003124962/04A patent/RU2324679C2/ru not_active IP Right Cessation
- 2002-01-22 RS YUP-568/03A patent/RS51010B/sr unknown
- 2002-01-22 BR BR0206637-8A patent/BR0206637A/pt not_active IP Right Cessation
- 2002-01-22 EP EP02734878A patent/EP1373202B1/fr not_active Expired - Lifetime
- 2002-01-22 CN CNB028039688A patent/CN1260213C/zh not_active Expired - Fee Related
- 2002-01-22 HR HR20030575A patent/HRP20030575B1/xx not_active IP Right Cessation
- 2002-01-22 MX MXPA03006548A patent/MXPA03006548A/es active IP Right Grant
- 2002-01-22 CZ CZ20031988A patent/CZ20031988A3/cs unknown
- 2002-01-22 EE EEP200300333A patent/EE05270B1/xx not_active IP Right Cessation
- 2002-01-22 AT AT02734878T patent/ATE294159T1/de active
- 2002-01-22 DK DK02734878T patent/DK1373202T3/da active
- 2002-01-22 KR KR1020037009509A patent/KR100882066B1/ko not_active Expired - Fee Related
- 2002-01-22 CA CA002435954A patent/CA2435954C/fr not_active Expired - Fee Related
- 2002-01-22 IL IL15706802A patent/IL157068A0/xx unknown
- 2002-01-22 WO PCT/IB2002/000161 patent/WO2002059087A1/fr not_active Ceased
- 2002-01-22 AU AU2002219455A patent/AU2002219455B2/en not_active Ceased
- 2002-01-22 UA UA2003076436A patent/UA73829C2/uk unknown
- 2002-01-22 SI SI200230156T patent/SI1373202T1/sl unknown
- 2002-01-22 SK SK908-2003A patent/SK286593B6/sk not_active IP Right Cessation
- 2002-01-22 PL PL361763A patent/PL209428B1/pl unknown
- 2002-01-22 JP JP2002559389A patent/JP4336106B2/ja not_active Expired - Fee Related
- 2002-01-22 HU HU0302797A patent/HU227535B1/hu not_active IP Right Cessation
- 2002-01-22 DE DE60203894T patent/DE60203894T2/de not_active Expired - Lifetime
- 2002-01-22 ES ES02734878T patent/ES2240748T3/es not_active Expired - Lifetime
- 2002-12-18 US US10/323,444 patent/US6750353B2/en not_active Expired - Fee Related
2003
- 2003-07-09 ZA ZA200305307A patent/ZA200305307B/xx unknown
- 2003-07-22 BG BG108017A patent/BG108017A/bg unknown
- 2003-07-23 IL IL157068A patent/IL157068A/en not_active IP Right Cessation
- 2003-10-03 US US10/677,344 patent/US7074940B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
RU2003124962A (ru)	2005-01-10
CA2435954A1 (fr)	2002-08-01
DE60203894T2 (de)	2006-01-19
SK9082003A3 (en)	2003-12-02
IL157068A0 (en)	2004-02-08
ES2240748T3 (es)	2005-10-16
CA2435954C (fr)	2008-06-03
UA73829C2 (en)	2005-09-15
US7074940B2 (en)	2006-07-11
SI1373202T1 (sl)	2005-12-31
CZ20031988A3 (cs)	2003-11-12
CN1260213C (zh)	2006-06-21
DK1373202T3 (da)	2005-05-17
HU227535B1 (en)	2011-08-29
BR0206637A (pt)	2004-08-03
IL157068A (en)	2009-09-01
KR100882066B1 (ko)	2009-02-10
YU56803A (sh)	2006-05-25
US20030109569A1 (en)	2003-06-12
SI20814A (sl)	2002-08-31
AU2002219455B2 (en)	2007-04-26
US20040072895A1 (en)	2004-04-15
RS51010B (sr)	2010-10-31
HUP0302797A2 (hu)	2003-11-28
DE60203894D1 (de)	2005-06-02
MXPA03006548A (es)	2004-10-15
ZA200305307B (en)	2004-07-09
US6750353B2 (en)	2004-06-15
RU2324679C2 (ru)	2008-05-20
PL209428B1 (pl)	2011-08-31
EE200300333A (et)	2003-10-15
HRP20030575B1 (hr)	2011-10-31
HUP0302797A3 (en)	2009-09-28
EP1373202A1 (fr)	2004-01-02
JP4336106B2 (ja)	2009-09-30
WO2002059087A1 (fr)	2002-08-01
JP2005503997A (ja)	2005-02-10
BG108017A (bg)	2004-08-31
EP1373202B1 (fr)	2005-04-27
HRP20030575A2 (en)	2005-06-30
CN1487921A (zh)	2004-04-07
SK286593B6 (sk)	2009-01-07
ATE294159T1 (de)	2005-05-15
KR20030077003A (ko)	2003-09-29
PL361763A1 (en)	2004-10-04

Legal Events

Date	Code	Title	Description
2003-12-15	HB1A	Correction of owner name or address
2005-08-15	HC1A	Change of owner name
2009-02-16	HC1A	Change of owner name
2010-02-15	HK1A	Erratum in gazette
2011-02-15	KB4A	Valid patent at the end of a year	Effective date: 20101231
2013-10-15	MM4A	Lapsed by not paying the annual fees	Effective date: 20130122

Publication	Publication Date	Title
EE200300333A (et)	2003-10-15	Mittekristallilise kaltsiumatorvastatiini valmistamismeetod
WO2001096334A3 (fr)	2002-09-12	Acides heteroarylalkanoiques utilises comme antagonistes des recepteurs d'integrine
DK0891325T3 (da)	2002-05-21	Para-substituerede phenylpropansyrederivater som integrinantagonister
BG103945A (bg)	2000-07-31	Производни на 4"-заместен-9-деоксо-9а-аза-9а- хомоеритромицин а
DK0894084T3 (da)	2002-10-14	Kanelsyrederivater og deres anvendelse som integrinantagonister
WO2001096307A3 (fr)	2002-08-15	Acides alcanoiques cycloalkyles comme antagonistes d'integrines
BR0317600A (pt)	2005-11-29	ácidos heteroarilalcanóicos como derivados de antagonistas de receptor de integrina
DK0734383T3 (da)	2002-10-14	Cykliske amidderivater som neurokinin-A-antagonister
WO2004096823A3 (fr)	2005-02-10	Nouveaux derives de ketolides
WO2001064645A3 (fr)	2001-12-27	Derives de quinoline utilises comme antagonistes alpha2
WO2001027110A3 (fr)	2001-09-20	Derives d'imidazo-3-yl-amine bicycliques substitues sur le sixieme chainon
NO973652D0 (no)	1997-08-08	5-(4-subst.-piperidinyl-1)-3-aryl-pentansyre og derivater som tachykininreseptor-antagonist
HK1053833A1 (zh)	2003-11-07	取代苯基法呢基转移酶抑制剂
CA2393757A1 (fr)	2001-06-14	Antagonistes du recepteur ccr5 de la cycloamine
WO2004111008A3 (fr)	2005-03-17	Utilisation d'un compose de formule i pour la preparation d'une composition pharmaceutique
ATE310010T1 (de)	2005-12-15	6-0-substitutierte eryththromycin-verbindungen und verfahrenen zu ihrer herstellung
ATE266029T1 (de)	2004-05-15	Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
NO983444D0 (no)	1998-07-24	Benzo(c)kinolizin derivater, deres fremstilling og anvendelse som 5<alfa>-reduktaseinhibitorer
DE69927997D1 (de)	2005-12-01	Neuartige pyrimidin-derivate und verfahren zu ihrer herstellung
MXPA02011402A (es)	2003-06-06	Un polimorfo v novedoso de torasemida.
MX9207204A (es)	1993-06-01	Preparado farmaceutico y procedimiento para su fabricacion.
TNSN05247A1 (en)	2007-06-11	Use of carbamazepine derivatives for the treatment of agitation in dementia patients
WO2005051349A3 (fr)	2005-07-28	Compositions pharmaceutiques de mirtazapine
WO2025162289A3 (fr)	2025-09-18	Forme cristalline d'un inhibiteur de pde4b et son utilisation pharmaceutique
ITMI930649A1 (it)	1994-10-01	Sali organici di glicosamminoglicani, procedimenti per la loro preparazione, composizioni farmaceutiche che li contengono